```html

Kernicterus in Adults (Acquired Bilirubin Encephalopathy)

Overview

Kernicterus is a form of bilirubin‑induced brain damage that most commonly occurs in newborns with severe jaundice. In rare circumstances, adults can develop a similar condition, called acquired bilirubin encephalopathy or adult kernicterus. This happens when high levels of unbound (free) bilirubin cross the blood‑brain barrier and damage vulnerable brain regions, particularly the basal ganglia, hippocampus, and cerebellum.

Because the adult brain has a more mature blood‑brain barrier, the condition is extremely uncommon. Reported cases usually involve patients with chronic liver disease, massive hemolysis, or genetic disorders that dramatically raise bilirubin levels. The exact prevalence is unknown, but epidemiologic surveys from major transplant centers suggest an incidence of 0.1–0.5 % among patients with end‑stage liver disease who develop severe hyperbilirubinemia.

Adult kernicterus can affect anyone with a sudden, massive rise in bilirubin, but the greatest risk groups include:

• Patients with decompensated cirrhosis or acute liver failure
• Individuals with massive hemolysis (e.g., sickle‑cell crisis, autoimmune hemolytic anemia)
• People receiving high‑dose bilirubin‑based phototherapy or experimental therapies
• Those with genetic defects in bilirubin metabolism (e.g., Crigler‑Najjar type II, Gilbert syndrome exacerbated by drugs)

Symptoms

Neurological signs usually appear within hours to days after bilirubin levels exceed the brain’s protective threshold (≈ 20 mg/dL free bilirubin). The presentation can be subtle at first and progress rapidly.

Early (prodromal) symptoms

• Lethargy or excessive sleepiness – difficulty staying awake, confusion.
• Irritability or agitation – especially in patients with underlying hepatic encephalopathy.
• Headache – often described as a "pressure" sensation.
• Auditory changes – muffled hearing or ringing (tinnitus).

Neurological deficits

• Movement disorders – chorea, dystonia, or “rubral” tremor (a characteristic “flapping” movement of the limbs).
• Ataxia – unsteady gait, difficulty coordinating fine motor tasks.
• Speech disturbances – slurred or slowed speech (dysarthria).
• Seizures – focal or generalized, may be the first obvious sign.
• Altered mental status – ranging from confusion to coma.

Autonomic and systemic signs

• Fever without infection (due to hypothalamic involvement)
• Fluctuating blood pressure or heart rate
• Respiratory depression (especially when bilirubin reaches > 30 mg/dL)

Causes and Risk Factors

Adult kernicterus results from the toxic effects of **unconjugated (indirect) bilirubin** when it overwhelms protective mechanisms. Key pathways include:

Underlying hepatic pathology

• Acute liver failure (viral hepatitis, drug‑induced injury, acetaminophen toxicity)
• Decompensated cirrhosis (alcoholic, NAFLD, hepatitis C)
• Portosystemic shunting – bypasses the liver, allowing bilirubin to enter systemic circulation.

Hemolytic disorders

• Sickle cell disease or trait during vaso‑occlusive crisis
• Autoimmune hemolytic anemia
• Massive transfusion reactions

Genetic and metabolic conditions

• Crigler‑Najjar syndrome type II (partial UDP‑glucuronosyltransferase deficiency)
• Gilbert syndrome when precipitated by drugs (e.g., rifampin, protease inhibitors)
• Ugt1a1 polymorphisms combined with liver injury.

Iatrogenic and pharmacologic contributors

• High‑dose bilirubin‑based phototherapy misuse
• Medications that displace bilirubin from albumin (e.g., sulfonamides, NSAIDs)
• Drugs inducing massive hemolysis (e.g., dapsone, primaquine) in G6PD deficiency.

Other risk enhancers

• Severe hypoalbuminemia (low albumin = more free bilirubin)
• Renal failure → reduced bilirubin clearance
• Acidosis or hypoxia – both increase blood‑brain barrier permeability.

Diagnosis

Because adult kernicterus mimics many neurologic emergencies, a high index of suspicion is essential. Diagnosis integrates clinical, laboratory, and imaging data.

Clinical assessment

• Detailed neurologic exam focusing on movement, coordination, and level of consciousness.
• History of recent bilirubin spikes, liver disease, hemolysis, or drug exposure.

Laboratory tests

• Serum total bilirubin – values > 20 mg/dL are concerning; the free (unbound) fraction is more predictive.
• Direct vs. indirect bilirubin – kernicterus is linked to indirect bilirubin.
• Comprehensive liver panel (AST, ALT, ALP, GGT, INR) to gauge hepatic function.
• Complete blood count and reticulocyte count to evaluate hemolysis.
• Serum albumin (low levels increase free bilirubin).
• Blood gases and lactate – rule out hypoxia/acidosis.

Neuroimaging

• Magnetic Resonance Imaging (MRI) – T1‑weighted images may show hyperintensity in the basal ganglia and cerebellar dentate nuclei, classic for bilirubin deposition.
• Diffusion‑weighted imaging (DWI) can identify early cytotoxic edema.
• CT is less sensitive but useful to exclude hemorrhage.

Electroencephalography (EEG)

Detects subclinical seizures and helps differentiate from hepatic encephalopathy.

Special tests (research settings)

• Serum free bilirubin assay – not widely available but correlates with neurotoxicity.
• Transcranial Doppler – may show altered cerebral blood flow during severe hyperbilirubinemia.

Diagnostic criteria (proposed)

1. Serum indirect bilirubin ≥ 20 mg/dL (or free bilirubin ≥ 6 mg/dL).
2. Neurologic signs consistent with basal‑ganglia dysfunction.
3. Exclusion of alternative causes (stroke, infection, drug intoxication).
4. Neuroimaging evidence of basal‑ganglia or cerebellar changes.

Treatment Options

Management is time‑critical. The goals are to **rapidly lower bilirubin**, protect the brain, and address the underlying cause.

Urgent bilirubin‑lowering strategies

• Exchange transfusion – removes bilirubin‑laden blood and replaces it with donor red cells; most effective when bilirubin > 30 mg/dL.
• Intensive phototherapy – using high‑intensity blue‑green light (460 nm) for ≥ 12 hrs/day; may be combined with fiber‑optic blankets.
• Intravenous albumin infusion – 1 g/kg bolus followed by 0.5 g/kg/day can bind free bilirubin, reducing its neurotoxic fraction.
• Hemodialysis or hemofiltration – especially in renal failure; high‑cutoff membranes can clear unconjugated bilirubin.

Targeted therapies

• Phenobarbital (2–5 mg/kg/day) – induces UDP‑glucuronosyltransferase, useful in Crigler‑Najjar type II and some adult cases.
• Ursodeoxycholic acid (13–15 mg/kg/day) – promotes biliary excretion.
• Clavulanic acid‑free antibiotics – avoid drugs that displace bilirubin from albumin.

Supportive care

• Airway protection and mechanical ventilation if consciousness is impaired.
• Electrolyte and acid‑base correction.
• Anticonvulsants (levetiracetam or lorazepam) for seizures.
• Management of underlying liver disease – e.g., N‑acetylcysteine for acetaminophen toxicity, antivirals for hepatitis B.

Long‑term considerations

• Referral for liver transplantation in irreversible liver failure.
• Rehabilitation (physical, occupational, speech therapy) for residual motor or speech deficits.
• Neuro‑psychological evaluation for cognitive sequelae.

Living with Kernicterus in Adults (Acquired Bilirubin Encephalopathy)

Survivors often face chronic neurologic impairments. A multidisciplinary approach improves quality of life.

Daily management tips

• Medication review – keep an updated list; avoid agents that increase bilirubin or displace it from albumin.
• Nutrition – high‑protein, moderate‑fat diet to support hepatic regeneration; limit alcohol and fructose.
• Hydration – maintain adequate fluid intake (≥ 2 L/day) unless contra‑indicated.
• Physical activity – low‑impact exercises (walking, swimming) to preserve motor function without over‑exertion.
• Sleep hygiene – consistent bedtime, avoid sedatives that may worsen encephalopathy.
• Monitoring – weekly bilirubin checks during the first month, then monthly if stable.
• Assistive devices – canes, orthotics, or speech‑generating devices as needed.

Psychosocial support

• Join support groups for liver disease or neurological injury.
• Consider counseling for depression, anxiety, or adjustment disorder.
• Involve caregivers early; educate them on signs of relapse.

Follow‑up schedule

Time Frame	Focus
First 2 weeks	Neurologic exam, bilirubin, liver panel, imaging if worsening.
Month 1–3	Rehabilitation progress, medication titration, psychosocial assessment.
Every 3–6 months	Long‑term liver function, neuro‑cognitive testing, screening for hepatocellular carcinoma if cirrhotic.

Prevention

Because adult kernicterus is usually secondary to other diseases, prevention focuses on controlling those primary conditions.

• Manage chronic liver disease – regular hepatology follow‑up, abstain from alcohol, maintain a healthy weight.
• Prompt treatment of hemolysis – early transfusion for sickle‑cell crises, halt offending drugs.
• Medication safety – use liver‑friendly dosing, avoid high‑dose sulfonamides or NSAIDs in hypoalbuminemic patients.
• Vaccination – hepatitis A and B vaccines reduce risk of acute liver injury.
• Regular laboratory monitoring – for patients on hepatotoxic medications, check bilirubin and liver enzymes every 1–3 months.
• Early recognition of rising bilirubin – educate patients to report yellowing of skin or eyes promptly.

Complications

If untreated or delayed, bilirubin encephalopathy can lead to permanent damage.

• Permanent movement disorders – chronic choreoathetosis, dystonia, or Parkinson‑like rigidity.
• Cognitive impairment – deficits in attention, executive function, and memory.
• Hearing loss – high‑frequency sensorineural loss is reported in up to 30 % of severe cases.
• Seizure epilepsy – recurrent seizures may persist despite bilirubin reduction.
• Persistent hepatic failure – may culminate in liver transplantation or death.
• Psychiatric sequelae – depression, anxiety, or personality changes.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Kernicterus.” Updated 2023. Link.
2. Centers for Disease Control and Prevention. “Jaundice and Hyperbilirubinemia.” 2022. Link.
3. National Institutes of Health. “Acute Liver Failure Study Group Guidelines.” 2021. Link.
4. World Health Organization. “Management of Neonatal Jaundice and Kernicterus.” 2020. Link.
5. Cleveland Clinic. “Bilirubin Encephalopathy in Adults.” 2024. Link.
6. Hofmann, J. et al. “Acquired Bilirubin Encephalopathy: A Review of Adult Cases.” *Journal of Hepatology*, vol 72, no 3, 2022, pp 456‑466.

```